Research programme: bradykinin-1 receptor inhibitors - Grunenthal
Latest Information Update: 14 Feb 2011
At a glance
- Originator Grunenthal
- Class Analgesics
- Mechanism of Action Bradykinin B1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Inflammation; Pain
Most Recent Events
- 14 Feb 2011 Preclinical development is ongoing in Germany
- 07 Jul 2005 Preclinical trials in Inflammation in Germany (unspecified route)